Научная литература
booksshare.net -> Добавить материал -> Медицина -> Насонов Е.Л. -> "Антифосфолипидный синдром" -> 182

Антифосфолипидный синдром - Насонов Е.Л.

Насонов Е.Л. Антифосфолипидный синдром — М.: Литтерра, 2004. — 440 c.
ISBN 5-98216-010-5
Скачать (прямая ссылка): antisindrom2004.pdf
Предыдущая << 1 .. 176 177 178 179 180 181 < 182 > 183 .. 184 >> Следующая

SHS-OOO4.qxd 21.11.2006 16:56 Page 43З'
ГЛАВА 14. Новые подходы к профилактике и лечению антифосфолипидного синдрома
96. Suzumura K, Yasuhara M, Tanaka K, Odawara A, Narita H, Suzuki T. An in vitro study of the hydroxyl radical scavenging properties of fluvastatin an HMG Co A reductase inhibitor. Chem Pharm Bull 1999; 47: 1010—12.
97. Hussein O, Schlezinger S Rosenblat M, Keidar S, Aviram W. Reduced susceptibility of low density lipoprotein to lipid peroxi-dation after flu-vastatin therapy is associated with the hypocho-lesterolaemic effect of the drug and its binding to the LDL. Atherosclerosis 1997; 128: 11—18.
98. Tomas M, Senti M, Garcia-Faria F, Vila J, Torrents A, Covas M, Marrugat J. Effect of sim-vastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholes-terolemic patients. Arterioscl Thromb Vase Biol 2000; 20: 2113—19.
99. Fuhrman B, Koren L, Volkova N, Keidar S, Hayek T, Aviram M. Atorvastatin therapy in hy-percholesterolemic patients suppresses cellular uptake of oxidized-LDL by differentiating mono-cytes. Atherosclerosis 2002; 164: 179—85.
100. Li DY, Chen HJ, Mehta JL. Statins inhibit oxidized-LDL-mediated LOX-1 expression, uptake of oxidized LDL and reduction in PKB phosphorylation. Cardiovasc Res 2001; 52:130—5.
101. Sumi D, Hayashi T, Thakur NK, et al. A HMG-CoA reductase inhibitor possesses a potent anti-atherosclerotic effect other than serum lipid lowering effects-the relevance of endothelial nitric oxide synthase and superoxide anion cavenging action. Atherosclerosis 2001; 155: 347—57.
102. Ganne F, Vasse M, Beaudeux JL, et al. Increased expression of u-PA and u-PAR on monocytes by LDL and Lp(a) lipoproteins-conse-quences for plasmin generation and monocyte adhesion. Thromb Haemost 1999; 81: 594—600.
103. Ganne F, Vasse M, Beaudeux JL, et al. Cerivastatin, an inhibitor of HMG-CoA reduc-tase, inhibits urokinase/urokinase-receptor expression and MMP-9 secretion by peripheral blood monocytesa possible protective mechanism against atherothrombosis. Thromb Haemost 2000; 84: 680—8.
104. Ferro D, Basili S, Alessandri C, et al. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis 2000; 149: 111—116.
105. Nagata K, Ishibashi T, Sakamoto T, et al. Rho-Rho-kinase is involved in the synthesis of tissue factor in human monocytes. Atherosclerosis 2002; 163: 39—47.
106. Ray JG. Why might statins prevent venous thromboembolism: what needs to done to know more? Expert Opinion Invest Drugs 2002; 11: 1659—1668.
107. Prandoni P, Bilora F, Marchiori A, et al. An association between atherosclerosis and venous thrombosis. New Engl J Med 2003; 348: 1435— 1441.
108. Abud-Mendoza C, Fuente Hrela, Cuevas-Orta E, et al. Therapy with statins in patients with refractory rheumatic disease: a preliminary study. Lupus 2003; 12: 607—611.
Новые антикоагулянты
1. Eriksson M, Christensen K, Lindahl TL, Larsson A. Pharmeceutical thrombosis prevention in cardiovascular disease. Expert Opin Invest Drugs 2002; 11: 553—563.
2. Leung LLK. New anticoagulants. UoToDate 2002; 10: 2.
3. Ruef J, Katus HA. New antithrombotic drugs on the horizon. Expert Opin Invest Drugs 2003; 12: 761—797.
4. Dunzendorfer S, Reinisch CM, Kaneider NC, et al. Inhibition of plasma-dependent monocyte chemokinesis and cytokine-triggering endothelial activation for neutrophil transmigration by administratuin of clopidogrel in man. Acta Med Austriaca 2002; 29: 100—106.
5. Klinkhardt U, Bauersach R, Adams J, et al. Clopidogrel but not aspirin reduces P-selectin expression and formation of platelet-leukocyte aggregates in patients with atheroscleritic vascular disease. Clin Pharm Ther 2003; 73: 232—241.
6. Klinkhardt U, Graff J, Harden S. Clopido-grel, but not abciximab, reduced platelet leukocyte conjugates and P-selectin expression in a human ex vivo in vitro model. Clin Rharm Ther 2002; 71: 176—185.
7. Silverberg MS, Erkan D, Sammaritano LR, Lockshin MD. Is there a role for non-warfarin agents in the ling-term management of antiphospho-lipid syndrome. ACR/ARHP Annual Scientific Meeting, Orlando, October 24—28, 2003; 862 (abst).
SHS-OOO4.qxd 21.11.2006 16:56 Page 434
Насонов Е.Л. Антифосфолипидный синдром.
8. Pierangeli SS, Liu X, Vega-Ostertag M, et al. An Antagonist of GPIIb/IIIa receptor in platelets reserves antiphospholipid-mediated thrombosis in vivo in f mouse model. ACR/ARHP Annual Scientific Meeting, Orlando, October 24—28, 2003; 327 (abst).
9. Kaiser B, Hoppensteadt DA, Fareed J. Tissue factor pathway inhibitor: an update of potential implications in the treatment of cardiovascular disorders. Expert Opin Invest Drugs 2001; 10: 1926—1935.
10. Bernard GR, Vincent J-L, Laterre P-F, et al. Efficasy and safety of recombinant human activated protein C for severe sepsis. New Engl J Med 2001; 344: 699—709.
11. Matthay MA. Severe sepsis — a new treatment with both anticoagulant and anti-inflammatory properties. New Engl J Med 2001; 344: 759—762.
12. Barband M, Guizzardi S, Calanni F, Marchi E, Babbini M. Int J Clin Lab Res 22, 179 (1992).
Предыдущая << 1 .. 176 177 178 179 180 181 < 182 > 183 .. 184 >> Следующая

Реклама

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed

Есть, чем поделиться? Отправьте
материал
нам
Авторские права © 2009 BooksShare.
Все права защищены.
Rambler's Top100

c1c0fc952cf0704ad12d6af2ad3bf47e03017fed